Ras in cancer and developmental diseases.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Genes & cancer

• Publication date

  2011-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1177/1947601911411084PMID 21779504PMCID PMC3128640
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival.

  2011cited by this paper
• Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer

  2011cited by this paper
• Mutant proteins as cancer-specific biomarkers

  2011cited by this paper
• Legius Syndrome in Fourteen Families

  2011cited by this paper
• Activation of K-RAS by co-mutation of codons 19 and 20 is transforming

  2011cited by this paper
• Abstract 133: A microRNA contribution to aberrant Ras activation in gastric cancer

  2011cited by this paper
• Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer.

  2011cited by this paper
• Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras

  2011cited by this paper
• Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders

  2011cited by this paper
• MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.

  2011cited by this paper
• Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer.

  2011cited by this paper
• Molecular pathways of urothelial development and bladder tumorigenesis.

  2010cited by this paper
• COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

  2010cited by this paper
• KRAS Mutation and Microsatellite Instability: Two Genetic Markers of Early Tumor Development That Influence the Prognosis of Colorectal Cancer

  2010cited by this paper
• Sorafenib: rays of hope in thyroid cancer.

  2010cited by this paper
• Clinical and genetic aspects of neurofibromatosis 1

  2010cited by this paper
• NRAS Mutations Are Rare in Colorectal Cancer

  2010cited by this paper
• K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer.

  2010cited by this paper
• Current status of imatinib as frontline therapy for chronic myeloid leukemia.

  2010cited by this paper
• A restricted spectrum of NRAS mutations causes Noonan syndrome

  2010cited by this paper
• Novel human pathological mutations. Gene symbol: SPRED1. Disease: Legius syndrome.

  2010cited by this paper
• Estimates of cancer incidence and mortality in Europe in 2008.

  2010cited by this paper
• Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

  2010cited by this paper
• Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium.

  2010cited by this paper
• Novel human pathological mutations. Gene symbol: SPRED1. Disease: Legius syndrome.

  2010cited by this paper
• Complications of radioactive iodine treatment of thyroid carcinoma.

  2010cited by this paper
• Chronic myeloid leukemia: a historical perspective.

  2010cited by this paper
• KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases

  2010cited by this paper
• Reviewer Acknowledgment

  2010cited by this paper
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

  2010cited by this paper
• Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography.

  2010cited by this paper
• Noonan Syndrome: Clinical Aspects and Molecular Pathogenesis

  2010cited by this paper
• Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

  2010cited by this paper
• KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis

  2010cited by this paper
• A Systems Perspective of Ras Signaling in Cancer

  2009cited by this paper
• The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

  2009cited by this paper
• Protein tyrosine phosphatase SHP‐2: A proto‐oncogene product that promotes Ras activation

  2009cited by this paper
• Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients.

  2009cited by this paper
• Mutation in SHOC2 promotes aberrant protein N-myristoylation and underlies Noonan-like syndrome with loose anagen hair

  2009cited by this paper
• Fast simultaneous detection of K-RAS mutations in colorectal cancer

  2009cited by this paper
• Noonan Syndrome and Related Disorders: A Review of Clinical Features and Mutations in Genes of the RAS/MAPK Pathway

  2009cited by this paper
• Activation of RAS family genes in urothelial carcinoma.

  2009cited by this paper
• Molecular pathology of differentiated thyroid cancer.

  2009cited by this paper
• Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

  2009cited by this paper
• Targeting the RET Pathway in Thyroid Cancer

  2009cited by this paper
• Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas

  2009cited by this paper
• KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis

  2009cited by this paper
• Endogenous expression of HrasG12V induces developmental defects and neoplasms with copy number imbalances of the oncogene

  2009cited by this paper
• Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair

  2009cited by this paper
• Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development.

  2009cited by this paper
• A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast‐flow vascular anomalies are caused by RASA1 mutations

  2008cited by this paper
• Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia

  2008cited by this paper
• Diabetes regulates small molecular weight G-protein, H-Ras, in the microvasculature of the retina: implication in the development of retinopathy.

  2008cited by this paper
• The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders

  2008cited by this paper
• KRAS mutations predict response to EGFR inhibitors.

  2008cited by this paper
• Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

  2008cited by this paper
• Clinical and biological significance of RAS mutations in multiple myeloma

  2008cited by this paper
• Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients.

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia

  2008cited by this paper
• RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations

  2008cited by this paper
• Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

  2008cited by this paper
• Noonan, Costello and cardio–facio–cutaneous syndromes: dysregulation of the Ras–MAPK pathway

  2008cited by this paper
• Potential role of sorafenib in the treatment of acute myeloid leukemia

  2008cited by this paper
• Leopard syndrome

  2008cited by this paper
• Clinical and molecular aspects of RAS related disorders

  2008cited by this paper
• Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype–phenotype relationships and overlap with Costello syndrome

  2007cited by this paper
• Ras oncogenes and their downstream targets.

  2007cited by this paper
• Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells

  2007cited by this paper
• Mutations in ZDHHC9, which encodes a palmitoyltransferase of NRAS and HRAS, cause X-linked mental retardation associated with a Marfanoid habitus.

  2007cited by this paper
• H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma

  2007cited by this paper
• MutationView/KMcancerDB: A database for cancer gene mutations

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Germline gain-of-function mutations in SOS1 cause Noonan syndrome

  2007cited by this paper
• Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective.

  2007cited by this paper
• Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.

  2007cited by this paper
• Germ Line Gain of Function with SOS1 Mutation in Hereditary Gingival Fibromatosis*

  2007cited by this paper
• Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy

  2007cited by this paper
• NRAS mutation causes a human autoimmune lymphoproliferative syndrome

  2007cited by this paper
• Germline gain-of-function mutations in RAF1 cause Noonan syndrome

  2007cited by this paper
• New insight into BRAF mutations in cancer.

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype

  2007cited by this paper
• Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

  2007cited by this paper
• Origin and prognostic value of circulating KRAS mutations in lung cancer patients.

  2007cited by this paper
• Deregulated Ras signaling in developmental disorders: new tricks for an old dog.

  2007cited by this paper
• B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis

  2007cited by this paper
• Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins

  2006cited by this paper
• PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects*

  2006cited by this paper
• Gene symbol: APC. Disease: Familial adenomatous polyposis coli. Accession #Hd0518.

  2006cited by this paper
• Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

  2006cited by this paper
• Signal transduction through Ras‐GTPase and Ca2+/ calmodulin‐dependent protein kinase II contributes to development of diabetes‐induced renal vascular dysfunction

  2006cited by this paper
• Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

  2006cited by this paper
• Germline KRAS mutations cause Noonan syndrome

  2006cited by this paper
• Genetics and biology of pancreatic ductal adenocarcinoma.

  2006cited by this paper
• Administration of anti-EGFR therapy: a practical review.

  2006cited by this paper
• Estimates of the cancer incidence and mortality in Europe in 2006.

  2006cited by this paper
• Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes

  2006cited by this paper

• Pimozide Reprograms the Ran GTPase-SCF Axis and Matrix Remodeling Pathways in Breast, Colorectal, and Pancreatic Cancer Models.

  2026cites this paper
• Fermented Bamboo Shoots as a Source of Natural HRAS Inhibitors: An Integrative Metabolomics, Pharmacokinetic, and Molecular Simulation Study for Cancer Therapy

  2026cites this paper
• Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.

  2026cites this paper
• Modulation of the 14-3-3σ/C-RAF “Auto”inhibited Complex by Molecular Glues

  2026cites this paper
• Genomic Profile and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Amplified Colorectal Cancer: A Study Based on a Japanese Cancer Genome Database

  2026cites this paper
• Pioneer in Molecular Biology: Conformational Ensembles in Molecular Recognition, Allostery, and Cell Function.

  2025cites this paper
• Exploring cellular plasticity and resistance mechanisms in lung cancer: Innovations and emerging therapies

  2025cites this paper
• Clinical significance of mutations in the NRAS, KRAS, and BRAF genes in patients with multiple myeloma

  2025cites this paper
• Targeting the MAPK Pathway in Cancer

  2025cites this paper
• Colon cancer cells evade drug action by enhancing drug metabolism

  2025cites this paper
• Analysis of Pan-Specific Inhibitors of Oncogenic Mutant Forms of KRAS GTPase.

  2025cites this paper
• Optogenetics with Atomic Precision—A Comprehensive Review of Optical Control of Protein Function through Genetic Code Expansion

  2025cites this paper
• Reengineering of a Proteomimetic Pan-Ras Inhibitor into a Ras Degrader.

  2025cites this paper
• Probing binding and allosteric mechanisms of the KRAS interactions with monobodies and affimer proteins: ensemble-based mutational profiling and thermodynamic analysis of binding energetics and allostery reveal diversity of functional hotspots and cryptic pockets linked by conserved communication ne

  2025cites this paper
• The role of germline and somatic mutations in predicting cancer-associated thrombosis: a narrative review

  2025cites this paper
• Ultra-sensitive detection of melanoma NRAS mutant ctDNA based on programmable endonucleases.

  2025cites this paper
• Impact of Mutational Status on Intracellular Effects of Cell‐Permeable CaaX Peptides in Pancreatic Cancer Cells

  2025cites this paper
• A Case of Advanced Non-Small Cell Lung Cancer With Hepatocellular Carcinoma-Like Features Responding to a Combination of Durvalumab, Tremelimumab, Carboplatin, and Nab-Paclitaxel

  2025cites this paper
• LZTR1 interacts with AIFM3 protein and negatively regulates Ras signaling by downregulating SHOC2 and phosphorylated p90RSK protein levels in apoptosis

  2025cites this paper
• Clinical application of the MEK inhibitor trametinib in dogs with oral squamous cell carcinoma

  2025cites this paper
• Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non–small cell lung cancer

  2025cites this paper
• A Conserved Architecture of Allosteric Communications and Regulatory Hotspots in the KRAS Complexes with Diverse Binding Proteins Controls Mechanisms of Effector Mimicry and Allosteric Modulation : Atomistic Revelations from Molecular Simulations and Mutational Scanning of Binding Energetics and All

  2025cites this paper
• Does the same mitochondrial variation exist in both autism spectrum disorders and different types of malignancies?

  2025cites this paper
• Expanding the Chemistry of Acyl Diazo Electrophile as a Tunable Warhead for Covalent Targeting of KRAS (G12D) Mutant.

  2025cites this paper
• Exploring MAPK and mTOR Pathways in Feline Thyroid Tumors

  2025cites this paper
• MicroRNA-1303 in cancer pathogenesis and therapy: clinical implications for biomarker development and targeted treatment strategies

  2025cites this paper
• Evolution of computational techniques against various KRAS mutants in search for therapeutic drugs: a review article

  2025cites this paper
• The Role of Connections Between Cellular and Tissue Mechanical Elements and the Importance of Applied Energy in Mechanotransduction in Cancerous Tissue

  2025cites this paper
• Switch II pocket inhibitor allosterically freezes KRASG12Dnucleotide-binding site and arrests the GTPase cycle.

  2025cites this paper
• Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?

  2025cites this paper
• KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.

  2025cites this paper
• Ensemble-Based Binding Free Energy Profiling and Network Analysis of the KRAS Interactions with DARPin Proteins Targeting Distinct Binding Sites: Revealing Molecular Determinants and Universal Architecture of Regulatory Hotspots and Allosteric Binding

  2025cites this paper
• Malignant Triton Tumor of the Ileocolic Mesentery with Neurofibromatosis Type 1: A Case Report and Literature Review

  2025cites this paper
• S-palmitoylation: A novel player in cancer and its emerging therapeutic implications

  2025cites this paper
• HybridGWOSPEA2ABC: a novel feature selection algorithm for gene expression data analysis and cancer classification.

  2025cites this paper
• Real time characterization of the MAPK pathway using native mass spectrometry

  2025cites this paper
• New depths: exploring the current landscape of colorectal cancer

  2025cites this paper
• Atomistic Profiling of KRAS Interactions with Monobodies and Affimer Proteins Through Ensemble-Based Mutational Scanning Unveils Conserved Residue Networks Linking Cryptic Pockets and Regulating Mechanisms of Binding, Specificity and Allostery

  2025cites this paper
• Dynamic Coupling of MAPK Signaling to the Guanine Nucleotide Exchange Factor GEF-H1

  2025cites this paper
• Modulation of the 14-3-3σ/C-RAF “auto”inhibited complex by molecular glues

  2025cites this paper
• The long noncoding RNA lnc-FANCI-2 intrinsically restricts RAS signaling in human papillomavirus type 16-infected cervical cancer cells

  2025cites this paper
• Role of Autophagy and AMPK in Cancer Stem Cells: Therapeutic Opportunities and Obstacles in Cancer

  2024cites this paper
• Correlation of LMP-1 expression with KRAS and Cyclin-D1 expressions in WHO type III NPC patients

  2024cites this paper
• Shared molecular, cellular, and environmental hallmarks in cardiovascular disease and cancer: Any place for drug repurposing?

  2024cites this paper
• Ionic control of small GTPase HRas using calmodulin.

  2024cites this paper
• Atypical Exon 2/3 Mutants G48C, Q43K, and E37K Present Oncogenic Phenotypes Distinct from Characterized NRAS Variants

  2024cites this paper
• Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches

  2024cites this paper
• KRAS inhibitors: resistance drivers and combinatorial strategies.

  2024cites this paper
• Exploring somatic mutations in BRAF, KRAS, and NRAS as therapeutic targets in Saudi colorectal cancer patients through massive parallel sequencing and variant classification

  2024cites this paper
• Disruption of deoxyribonucleotide triphosphate biosynthesis leads to RAS proto-oncogene activation and perturbation of mitochondrial metabolism

  2024cites this paper
• Oxidative Stress and Cancer Therapy: Controlling Cancer Cells Using Reactive Oxygen Species

  2024cites this paper
• Hyperthermia-mediated cell death via deregulation of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase signaling

  2024cites this paper
• Structural modifications and kinetic effects of KRAS interactions with HRAS and NRAS: an in silico comparative analysis of KRAS mutants

  2024cites this paper
• KRAS (Kirsten rat sarcoma) in modern oncology—The molecular pathological point of view

  2024cites this paper
• Cancer, metastasis, and the epigenome

  2024cites this paper
• IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers

  2024cites this paper
• The Multifaceted Role of miR-21 in Pancreatic Cancers

  2024cites this paper
• Impact of a High‐Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor

  2024cites this paper
• Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration

  2024cites this paper
• DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras

  2024cites this paper
• Photocontrol of small GTPase Ras fused with a photoresponsive protein.

  2024cites this paper
• Mutations influence the conformational dynamics of the GDP/KRAS complex

  2024cites this paper
• GTP-Bound N-Ras Conformational States and Substates Are Modulated by Membrane and Point Mutation

  2024cites this paper
• Cellular and Exosomal MicroRNAs: Emerging Clinical Relevance as Targets for Breast Cancer Diagnosis and Prognosis

  2024cites this paper
• Signaling Pathways in Clear Cell Renal Cell Carcinoma and Candidate Drugs Unveiled through Transcriptomic Network Analysis of Hub Genes

  2024cites this paper
• Bougainvillea glabra Choisy bracts extract in free and liposomal forms reduce hyperplasia induced by let‐60gain‐of‐function in Caenorhabditis elegans

  2024cites this paper
• Unraveling the Significance of Mg2+ Dependency and Nucleotide Binding Specificity of H-RAS.

  2024cites this paper
• Insulin Resistance: The Increased Risk of Cancers

  2024cites this paper
• Changes in Cells Associated with Insulin Resistance

  2024cites this paper
• Genomic Alterations in Melanocytic Tumors: A Review of Spitz Tumors, Blue Nevi, Deep Penetrating Melanocytomas and Pigmented Epithelioid Melanocytomas

  2024cites this paper
• Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas

  2024cites this paper
• Partial Hepatectomy Promotes the Development of KRASG12V-Induced Hepatocellular Carcinoma in Zebrafish

  2024cites this paper
• An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies

  2024cites this paper
• Combined HRAS and NRAS ablation induces a RASopathy phenotype in mice

  2024cites this paper
• Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen

  2024cites this paper
• “Carnosine-Niosomal Delivery System for Targeted Cancer Therapy”

  2024cites this paper
• Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening

  2023cites this paper
• Colon Cancer Cells Evade Drug Action by Enhancing Drug Metabolism

  2023cites this paper
• Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors

  2023cites this paper
• Targeting breast cancer using phytoconstituents: Nanomedicine-based drug delivery

  2023cites this paper
• Study of hesperetin effect on modulating transcription levels of MLH1 and MSH2 genes in SKBR3 breast cancer cell line

  2023cites this paper
• Memory T Cells in the Immunoprevention of Cancer: A Switch from Therapeutic to Prophylactic Approaches.

  2023cites this paper
• 1,3-Dichloroadamantyl-Containing Ureas as Potential Triple Inhibitors of Soluble Epoxide Hydrolase, p38 MAPK and c-Raf

  2023cites this paper
• Biochemical and biophysical characterization of the RAS family small GTPase protein DiRAS3.

  2023cites this paper
• Computational design and validation of effective siRNAs to silence oncogenic KRAS

  2023cites this paper
• FTase inhibitors and cancer: prospects for use in targeted therapies

  2023cites this paper
• Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial

  2023cites this paper
• COX2-Inhibitory and Cytotoxic Activities of Phytoconstituents of Matricaria chamomilla L.

  2023cites this paper
• Clinical Analysis of the Colorectal Cohort within the Wales Cancer Biobank: A Study of Outcomes and Genetic Screening

  2023cites this paper
• Targeting Ras with protein engineering

  2023cites this paper
• Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma

  2023cites this paper
• Defining bone fide effectors of RAS GTPases

  2023cites this paper
• Investigating the effects of cysteine-118 oxidation on G12D KRas structure and dynamics: insights from MD simulations

  2023cites this paper
• 2'-Deoxy Guanosine Nucleotides Alter the Biochemical Properties of Ras.

  2023cites this paper
• Genetically Encoded Aminocoumarin Lysine for Optical Control of Protein–Nucleotide Interactions in Zebrafish Embryos

  2023cites this paper
• Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models

  2023cites this paper
• Two-dimensional molecular condensation in cell signaling and mechanosensing

  2023cites this paper
• The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.

  2023cites this paper
• TARGETING THE MUTANT REGION IN K-RAS RNA INTERFERENCE CONTROLLING CELL PROLIFERATION AND PROGRAMMED CELL DEATH IN LIVER CANCER CELLS

  2023cites this paper
• Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

  2023cites this paper